Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 6, 2010, Pages 418-427

  Van De Maele, Boudewijn ^a   Fabbri, Leonardo M ^b   Martin, Carmen ^c   Horton, Rachael ^c   Dolker, Michael ^d   Overend, Tim ^c  

^a Campus H Serruys   (Belgium)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiovascular safety; COPD; Glycopyrronium; Indacaterol; NVA237; QVA149

Indexed keywords

BRONCHODILATING AGENT; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; PLACEBO; QVA 149; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; COUGHING; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NECK PAIN; PHARYNGITIS; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TORSADE DES POINTES; VITAL SIGN; XEROSTOMIA;

ADMINISTRATION, INHALATION; AGED; ATRIAL FIBRILLATION; BLOOD PRESSURE; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; GLYCOPYRROLATE; HEART RATE; HUMANS; HYPERKALEMIA; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TACHYCARDIA, VENTRICULAR;

EID: 78650491035     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2010.528812     Document Type: Article

References (35)

1. World Health Organisation (WHO). World Health Statistics. Available at: http://www.who.int/whosis/whostat/EN WHS08 Full.pdf Accessed: 10 November 2008.
2. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2009. Available at http://www.goldcopd.com Accessed: 23 December 2009.
3. Cazzola M., Santus P, Verga M, Mondoni M, Di Marco F, Matera MG. The functional impact of adding salmeterol to tiotropium in patients with stable COPD. Respir Med 2004; 98:1214-1221.
4. Brashier B, Jantikar A, Maganji M, Raghupathy A, Valsa S, Gokhale P, Mahadik P, Gogtay J, Salvi SS. Addition of formoterol to tiotropium produces better FEV1 and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD (Abstract). Chest 2005; 128:258s.
5. Cazzola M, Noschese P, Salzillo A, De Giglio C, D'Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005; 99:524-528.
6. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJG. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214-222.
7. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJG. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509-517.
8. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545-555. (Pubitemid 351650535)
9. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255-262.
10. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008a; 102:1511-1520.
11. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102:479-487.
12. Tashkin D, Pearle J, Iezzoni D, Varghese ST. Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease: Findings from a randomized, placebo-controlled trial. J COPD 2009; 6:17-25.
13. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010; 10(7):995-1004.
14. Cazzola M, Matera MG. The effective treatment of COPD: Anti-cholinergics and what else? Drug Disc Today: Therapeut Strateg 2006; 3(3):277-286.
15. Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23(4):257-267.
16. Roig J, Hernando R, Mora R. Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist. The Open Respiratory Medicine Journal 2009, 3:27-30.
17. Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007;52:833-851.
18. Ray NC, Alcaraz L. Muscarinic antagonist-β2- adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review Expert Opin. Ther Patents 2009;19(1):1-12.
19. Sarria B, Naline E, Zhang Y, Cortijo J, Molimard M, Moreau J, Therond P, Advenier C, Morcillo EJ. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol Lung Cell Mol Physiol 2002; 283(5):L1125-L1132.
20. Salpeter SR, Omiston TM, Salpeter EE. Cardiovascular effects of β2-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309-2321.
21. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439-1450.
22. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulmon Pharmacol Ther 2007; 20:495-502.
23. Rabe KF. Anticholinergic Drugs for the Treatment of COPD Are Safe. . . Are They? Chest 2010; 137:1-3.
24. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102:1033-1044.
25. Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M. Safety, tolerability and efficacy of inda-caterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20:740-749.
26. Dahl RP, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled β2- agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65:473-479.
27. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol versus Tiotropium. Am J Respir Crit Care Med 2010; 182:155-162.
28. Khindri S, Sabo R, Harris S, Jennings S, Drollman AF. Cardiac safety of indacaterol-no clinical effect on QT in healthy subjects. Eur Respir J 2009; 34(Suppl. 53):2031.
29. Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK. Safety and tolerability of NVA237, a once-daily long-acting mus-carinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010; 23:438-444.
30. Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, Dolker M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010; 104:1482-1489.
31. Bremmer P, Woodmarn K, Burgess C, Crane J, Purdie G, Pearce N, Beasley RA. Comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6:204-210.
32. Rodrigo G, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD. Chest 2008; 133:1079-1087.
33. Welleck S. Testing Statistical Hypotheses of Equivalence, 1st Edition, London: Chapman and Hall, 2002.
34. Ferguson G, Funck-Bretano C, Fischer T, Darken P, Reis-ner C. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817-1824.
35. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20-30.